Document Detail


Cost-effectiveness of ritodrine and fenoterol for treatment of preterm labor in a low-middle-income country: a case study.
MedLine Citation:
PMID:  18380627     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: In countries with high income, tocolytic therapy with beta-mimetic agents is a cost-effective strategy compared to placebo. In our study, the cost-effectiveness of two beta-mimetic agents, ritodrine and fenoterol, used in the management of preterm labor was compared in the setting of a low-middle-income transitional country, Serbia & Montenegro. METHODS: This case study was conducted at the Gynecology-Obstetrics Clinic, Clinical Center "Kragujevac," in Kragujevac, Serbia & Montenegro, between October 2004 and January 2006. In total, 235 pregnant patients with threatened preterm labor were enrolled, but 35 were lost to follow-up. Of the remaining 200 patients, 85 were given ritodrine, and 115 fenoterol. The perspective of Republic Institute for Health Insurance in Serbia was taken into account. Only direct costs were calculated; primary outcomes of the study were length of pregnancy (in weeks), time passed from the onset of uterine contractions to delivery (in weeks), and score on modified Flanagan's quality-of-life scale for chronic diseases, measured after discharge from hospital. RESULTS: Prolongation of pregnancy was significantly longer in the fenoterol group (12.7 +/- 8.4 weeks) than in the ritodrine group (11.6 +/- 7.1 weeks). The mean duration of hospitalization was shorter in the fenoterol group (11.9 +/- 8.8 days) than in the ritodrine group (14.9 +/- 11.3 days). The treatment with fenoterol was less costly and more cost-effective than the treatment with ritodrine, but the difference in cost-effectiveness was not statistically significant. The cost of treatment per gained week of pregnancy prolongation was 3345.51 +/- 7668.04 CSD in the fenoterol group, and 4181.96 +/- 12,069.83 CSD in the ritodrine group. CONCLUSIONS: The observed differences in treatment costs and duration of hospitalization per patient did not translate into significant differences in cost-effectiveness ratios, because of low costs of hospitalization and human labor in Serbian health system. Nevertheless, fenoterol treatment still has a tendency to be more cost-effective, and its lower acquisition cost is an advantage to this treatment option.
Authors:
Mihajlo Jakovljevic; Mirjana Varjacic; Slobodan M Jankovic
Related Documents :
16282227 - Provider support of spontaneous pushing during the second stage of labor.
16967637 - Anaphylaxis to cefazolin during labor secondary to prophylaxis for group b streptococcu...
7076337 - Incidence and significance of the unengaged fetal head in nulliparas in early labor.
10561617 - Cesarean delivery of twins and neonatal respiratory disorders.
25460647 - Postnatal weight growth and trihalomethane exposure during pregnancy.
16595207 - Preimplantation genetic diagnosis significantly reduces pregnancy loss in infertile cou...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research     Volume:  11     ISSN:  1524-4733     ISO Abbreviation:  Value Health     Publication Date:    2008 Mar-Apr
Date Detail:
Created Date:  2008-04-02     Completed Date:  2008-04-16     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100883818     Medline TA:  Value Health     Country:  United States    
Other Details:
Languages:  eng     Pagination:  149-53     Citation Subset:  IM    
Affiliation:
University of Kragujevac, Kragujevac, Serbia & Montenegro.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Cohort Studies
Cost-Benefit Analysis / economics
Female
Fenoterol / economics*,  therapeutic use
Hospitals, University / statistics & numerical data
Humans
Montenegro
National Health Programs
Obstetric Labor, Premature / drug therapy*,  economics*
Pregnancy
Ritodrine / economics*,  therapeutic use
Social Class
Tocolytic Agents / economics*,  therapeutic use
Treatment Outcome
Yugoslavia
Chemical
Reg. No./Substance:
0/Tocolytic Agents; 13392-18-2/Fenoterol; 26652-09-5/Ritodrine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Probabilistic cost-effectiveness modeling of different breast cancer screening policies in Slovenia.
Next Document:  Cost-effectiveness of rosuvastatin in the prevention of ischemic heart disease in Portugal.